Influence of exploratory celiotomy on the management of carcinoma of cervix

Sudarsanam, Anam; Charyulu, Komanduri; Averette, Hervy E.; Hintz, Brace L.; Belinson, Jerome L.

doi:10.1016/0360-3016(77)90313-3

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients who have histologic evidence of metastatic disease to the lymph nodes have a worse prognosis. Patients with positive para-aortic lymph nodes represent about 20% of all patients diagnosed with ICC in the United States [57][58][59][60][61][62][63]. Although there are no prospective data to confirm, node positivity rates are often higher in HIVinfected women with cervical cancer.…”

Section: Natural History Of Human Papillomavirus Infection In Hiv-unimentioning

confidence: 99%

Issues in cervical cancer incidence and treatment in HIV

Einstein¹,

Phaëton²

2010

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Section: Natural History Of Human Papillomavirus Infection In Hiv-unimentioning

confidence: 99%

Issues in cervical cancer incidence and treatment in HIV

Einstein¹,

Phaëton²

2010

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Despite these exciting results, there remains a subset of patients with a relatively poor prognosis. This includes patients with histologic evidence of metastatic disease to the lymph nodes [5–9]. …”

Section: Introductionmentioning

confidence: 99%

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Farley

Sill

Birrer

et al. 2011

Gynecologic Oncology

View full text Add to dashboard Cite

Background The purpose of this study was to evaluate the safety and efficacy of cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity, with cisplatin and to explore associations between EGFR protein expression with patient demographics or clinical outcome. Methods Women with advanced, persistent, or recurrent carcinoma of the cervix were eligible. The women received cisplatin at 30 mg/m2 days 1 and 8 with a loading dose of cetuximab at 400 mg/m2 followed by 250 mg/m2 days 1, 8, and 15 in a 21 day cycle. Adverse events were assessed with CTCAE v 3.0. Primary measure of efficacy was tumor response by RECIST. The study was stratified by prior chemotherapy (CT). EGFR protein expression in pre-treatment tumor was analyzed by immunohistochemistry. Results Between September 2004 and March 2008, 76 patients were enrolled. Of these, 69 were eligible and evaluable; 44 (64%) received prior chemotherapy. There were 4 responses in each group, prior chemotherapy and no chemotherapy, 9% and 16%, respectively. Grade 4 toxicities included anemia (1), allergy (1), metabolic (1), and vascular (1). The most common grade 3 toxicities were metabolic (15), dermatologic (8), fatigue (6), and gastrointestinal (6). EGFR protein was expressed in 47/48 (98%) of tumors analyzed with a median cellular expression of 81%. Exploratory analyses revealed a trend between the percentage of cells expressing EGFR protein and PFS (hazard ratio =1.76, 95% confidence interval=0.96–3.21). Conclusions The combination of cetuximab with cisplatin was adequately tolerated but did not indicate additional benefit beyond cisplatin therapy.

show abstract

“…Como se observa en la Tabla III, para las pacientes con una etapa IB el riesgo de ganglios pelvianos positivos es de aproximadamente 17%(15)(16)(17)(18)(19)(20)(21)(22)(23). En la Tabla IV se detalla el porcentaje de compromiso ganglionar lumboaórtico en pacientes con etapa II y III (16,4 y 28,6% respectivamente), según los trabajos publicados en la literatura(3,4,7,8,10,(24)(25)(26)(27)(28)(29).…”

unclassified